Navigation Links
Targeting aggressive breast cancers by putting them to sleep
Date:3/25/2008

It is well established that Id1, a gene normally produced only in embryonic development, is reactivated in many 'solid' cancers, or carcinomas.

In the case of breast cancer, the Id1 gene is active only in the more aggressive and metastatic varieties of cancer. Typically those cancers do not possess the oestrogen receptor, and for that reason cannot be treated with Tamoxifen (a drug that interferes with the action of oestrogen), the most effective breast cancer treatment available.

The outcomes for women with breast cancers producing Id1 are therefore much worse than for women with other forms of breast cancer.

Findings by Dr Alex Swarbrick, a scientist at Sydney's Garvan Institute of Medical Research, in collaboration with Professor J. Michael Bishop, Nobel Prize winner and Chancellor of the University of California San Francisco (UCSF), may provide hope for such women in the future. Their article, published online this week in the international journal Proceedings of the National Academy of Sciences, USA (PNAS), shows that Id1 drives some breast cancers.

Dr Swarbrick initiated the Id1 project three years ago while working as a post doctoral researcher in the laboratory of Professor Bishop He conducted much of the experimental work for the project at UCSF, then analysed the data and tissue samples at Garvan. "We happened to ask the right questions about the right gene," he said. "Up to that point, no-one else had asked whether or not Id1 actually contributed to the origin and behaviour of breast cancer".

"By artificially activating the Id1 protein in mouse mammary glands, we demonstrated that Id1 indeed contributes to cancer - and that mammary cancers with high levels of Id1 become very aggressive and highly metastatic."

"We also showed that if we genetically switch off the Id1 gene in an established tumour, those mice live much longer than mice with continual Id1 expression in their tumour. In fact about 40% of them were cured and the tumours just shrank away."

"One of our most surprising findings was that although the tumours went away, the cells making up the tumour didn't die, as you'd expect."

Instead, the vanishing tumours underwent 'senescence' a tumour suppressive mechanism that scientists are only just beginning to understand. The word is derived from the Latin 'senescere', to grow old. For cells, it means they permanently lose the ability to divide.

Swarbrick believes that as well as trying to kill aggressive breast cancers, it may also be effective to drive them into senescence, to put them to sleep. "You induce a terminal sleep, and then the immune system just gobbles them up."

"Many cancers mutate the genes involved in cell death, so it's hard to kill them. Our results suggest that in the future if we can therapeutically target the genes controlling senescence, such as Id1, we can force these tumours to senesce."


'/>"/>

Contact: Alison Heather
A.heather@garvan.org.au
61-292-958-128
Research Australia
Source:Eurekalert

Related medicine news :

1. Investigational Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity in Humans, Study in Nature Medicine Finds
2. Chronic infection persists by targeting stromal cell network in lymphoid organs
3. Prime Access Creates Groundbreaking Ads Targeting Urban Teens for the White Houses National Youth Anti-Drug Media Campaign
4. Isis Adds New Drug to Its Development Pipeline: ISIS 388626 Targeting SGLT2 for the Treatment of Type 2 Diabetes
5. Phase I pharmacokinetic study of ECO-4601, a novel bifunctional targeting agent
6. Anticancer Drugs Targeting the ErbB (EGFr/HEr2) Pathway Alone Generated Global Sales of Nearly $5 Billion in the First Nine Months of 2007
7. Tobacco marketers targeting teens near schools
8. APIC launches Targeting Zero initiative to eradicate infections deemed preventable by CMS
9. New Research Shows Nutrition Programs Targeting Pregnancy and First 24 Months of Life Dramatically Improve Child Survival and Overall Health
10. Targeting gut bugs could revolutionize future drugs, say researcher
11. Targeting astrocytes slows disease progression in ALS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2017)... ... April 29, 2017 , ... ... company, today announced the launch of DonorBridge, its process and engagement analytics ... of software innovation and industry expertise with predictive analytics to help nonprofits ...
(Date:4/29/2017)... ... ... More than half of Americans suffering from noise-induced hearing loss do not ... causes hearing loss? May 1 marks the beginning of Better Hearing & Speech Month—a ... as schedule a hearing evaluation for anyone with concerns about his/her hearing. , Approximately ...
(Date:4/28/2017)... ... April 28, 2017 , ... It's not always common knowledge ... of illnesses that are unclear as to whether or not they are contagious, and ... one of these illnesses. So, FindaTopDoc took a look into the matter. , ...
(Date:4/28/2017)... ... April 28, 2017 , ... GlycoMark, Inc. announced ... test throughout the Northeast U.S. , GlycoMark is the only clinically available ... test provides a clinically proven one- to two-week measure of hyperglycemic excursions, often ...
(Date:4/28/2017)... ... April 28, 2017 , ... Children ... to more adverse experiences than children in the general population. That’s because foster ... neglect or other family challenges. While no fault of their own, youth who ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the "Company"), announces that it ... 2017 at the Sheraton Hotel in Toronto, Ontario ... the Company is scheduled to present on Tuesday, May 2 at ... Chairman of the Board, Tony Holler will also attend ... For more details ...
(Date:4/19/2017)... April 19, 2017 Global Surgical Drainage Device ... tubes used to remove excess liquid and air. The ... urine, bile or lymph. Surgical drains are used in ... as orthopedics surgery, cardiovascular surgery, neurosurgery, plastic surgery etc. ... to prevent accumulation of fluid e.g. blood or pus. ...
(Date:4/19/2017)... 19, 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... company developing new treatments for cancer and other ... its previously announced underwritten public offering of 23,625,084 ... offering price of $2.00 per share, before deducting ... payable by Sorrento.  The net proceeds to Sorrento ...
Breaking Medicine Technology: